Mineralys Therapeutics (NASDAQ:MLYS) Director Daphne Karydas Sells 15,000 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Daphne Karydas sold 15,000 shares of Mineralys Therapeutics stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $45.99, for a total transaction of $689,850.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Mineralys Therapeutics Stock Down 6.4%

NASDAQ MLYS opened at $44.29 on Friday. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $47.65. The company has a 50 day moving average price of $40.05 and a 200 day moving average price of $23.78. The firm has a market cap of $3.51 billion, a PE ratio of -15.01 and a beta of 0.40.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. On average, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MLYS has been the topic of several research analyst reports. The Goldman Sachs Group boosted their target price on Mineralys Therapeutics from $32.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Bank of America boosted their price target on Mineralys Therapeutics from $38.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. HC Wainwright upped their price objective on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday. Wells Fargo & Company lifted their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Jefferies Financial Group boosted their target price on shares of Mineralys Therapeutics from $15.00 to $26.00 and gave the stock a “hold” rating in a research report on Wednesday, September 3rd. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $46.67.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. raised its position in Mineralys Therapeutics by 26.7% during the 1st quarter. RA Capital Management L.P. now owns 6,147,280 shares of the company’s stock worth $97,619,000 after buying an additional 1,296,296 shares during the last quarter. SR One Capital Management LP increased its stake in shares of Mineralys Therapeutics by 55.1% in the first quarter. SR One Capital Management LP now owns 3,127,933 shares of the company’s stock worth $49,672,000 after acquiring an additional 1,111,111 shares during the period. Jennison Associates LLC increased its stake in shares of Mineralys Therapeutics by 82.9% in the first quarter. Jennison Associates LLC now owns 1,979,033 shares of the company’s stock worth $31,427,000 after acquiring an additional 897,027 shares during the period. Orbimed Advisors LLC purchased a new position in shares of Mineralys Therapeutics during the second quarter worth $10,288,000. Finally, Stempoint Capital LP lifted its position in Mineralys Therapeutics by 605.3% during the second quarter. Stempoint Capital LP now owns 631,586 shares of the company’s stock valued at $8,551,000 after purchasing an additional 756,586 shares during the period. Institutional investors and hedge funds own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.